| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3283419 | Clinical Gastroenterology and Hepatology | 2010 | 4 Pages |
Abstract
Tumor necrosis factor-α antagonists such as infliximab or adalimumab may be a new treatment option for patients with severe refractory lymphocytic enterocolitis not responding to corticosteroids.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Ghazaleh Aram, Theodore M. Bayless, Zong-Ming Chen, Elizabeth A. Montgomery, Mark Donowitz, Francis M. Giardiello,